[Federal Register: September 11, 2008 (Volume 73, Number 177)]
[Notices]
[Page 52861-52862]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr11se08-72]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2006-N-0178] (formerly Docket No. 2006N-0362)
Draft Guidance for Industry and Food and Drug Administration
Staff; Class II Special Controls Guidance Document: Absorbable
Hemostatic Device; Availability; Reopening of Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; reopening of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is reopening until
October 14, 2008, the comment period for a draft guidance entitled
``Class II Special Controls Guidance Document: Absorbable Hemostatic
Device.'' The draft guidance describes a means by which the absorbable
hemostatic device may comply with the requirements of special controls
if it is reclassified. FDA is reopening the comment period to update
comments and to receive any new information. Elsewhere in this issue of
the Federal Register, FDA is reopening the comment period on a proposed
rule to reclassify the absorbable hemostatic device from class III
(premarket approval) into class II (special controls).
DATES Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency considers your comments on
this draft guidance before it begins work on the final version of the
guidance, submit written or electronic comments on the draft guidance
October 14, 2008.
ADDRESS: Submit written comments to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Submit electronic comments to http://
www.regulations.gov. See the SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance document.
[[Page 52862]]
FOR FURTHER INFORMATION CONTACT: David Krause, Center for Devices and
Radiological Health (HFZ-410), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 240-276-3638.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of October 31, 2006 (71 FR 63728), FDA
published a proposed rule to reclassify the absorbable hemostatic
device intended to produce hemostasis from class III (premarket) into
class II (special controls). In the same issue of the Federal Register
(71 FR 63774), FDA published a notice of availability of a draft
guidance document entitled ``Class II Special Controls Guidance
Document: Absorbable Hemostatic Device.'' FDA invited interested
persons to comment on the draft guidance document by January 29, 2007.
In the Federal Register of May 8, 2007 (72 FR 26134), FDA published a
notice reopening the comment period for 30 days.
On July 2, 2007, FDA received a petition under 21 CFR 10.30 and
10.35 requesting that the agency refrain from issuing a final
regulation for the proposed reclassification and the draft special
controls guidance for the absorbable hemostatic device until an updated
and complete administrative record is made available to the public. The
petitioner also requested that FDA reopen the rulemaking for the
proposed reclassification to allow submission of comments based on the
administrative record. Elsewhere in this issue of the Federal Register,
FDA is reopening the comment period on the proposed rule for 30 days.
Because the issues presented by the guidance document are intertwined
with those presented by the proposed rule, FDA is reopening the comment
period on the guidance document for the same period.
II. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by using the Internet. To receive the draft guidance document
entitled ``Class II Specials Controls Document: Absorbable Hemostatic
Device,'' you may either send an e-mail request to dsmica@fda.hhs.gov
to receive an electronic copy of the document, or send a fax request to
240-276-3151 to receive a hard copy. Please use the document number
1558 to identify the guidance you are requesting.
CDRH maintains an entry on the Internet for easy access to
information including text, graphics, and files that may be downloaded
to a personal computer with Internet access. Updated on a regular
basis, the CDRH home page includes device safety alerts, Federal
Register reprints, information on premarket submissions (including
lists of approved applications and manufacturers'' addresses), small
manufacturer'' assistance, information on video conferencing and
electronic submissions, Mammography Matters, and other device-oriented
information. The CDRH Web site may be accessed at http://www.fda.gov/
cdrh. A search capability for all CDRH guidance documents is available
at http://www.fda.gov/cdrh/guidance.html. Guidance documents are also
available at http://www.regulations.gov.
III. Request for Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments on the draft guidance
document. Submit a single copy of electronic comments or two paper
copies of any mailed comments, except that individuals may submit one
paper copy. Comments are to be identified with the docket number found
in brackets in the heading of this document. Received comments may be
seen in the Division of Dockets Management between 9 a.m. and 4 p.m.
Monday through Friday.
Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments submissions will be accepted by FDA through
FDMS only.
Dated: September 4, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-21197 Filed 9-10-08; 8:45 am]
BILLING CODE 4160-01-S